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BACKGROUND AND PURPOSE
Activation of hepatic stellate cells (HSCs) is a crucial step in the pathogenesis of hepatic fibrosis. Histone deacetylase (HDAC)
is an attractive target in liver fibrosis because it plays a key role in gene expression and cell differentiation. We have developed
a HDAC inhibitor, N-hydroxy-7-(2-naphthylthio)heptanomide (HNHA), and investigated the anti-fibrotic activity of HNHA
in vitro and in vivo.
EXPERIMENTAL APPROACH
We investigated the anti-fibrotic effect of HNHA on mouse and human HSC activation in vitro and in the liver of bile
duct-ligated (BDL) rats in vivo using cell proliferation assays, cell cycle analysis, biochemical assay, immunohistochemistry and
Western blots. Liver pathology was assessed with histochemical techniques.
KEY RESULTS
HNHA inhibited proliferation and arrested the cell cycle via p21 induction in HSCs. In addition, HNHA induced apoptosis of
HSCs, which was correlated with reduced COX-2 expression, NF-κB activation and cell death signals. HNHA restored liver
function and decreased the accumulation of extracellular matrix in the liver via suppression of HSC activation in BDL rats
in vivo. HNHA administration also increased survival in BDL rats.
CONCLUSIONS AND IMPLICATIONS
HNHA improved liver function, suppressed liver fibrosis and increased survival of BDL rats, accompanied by reduction of cell
growth, activation and survival of HSCs. These findings show that HNHA may be a potent anti-fibrosis agent against hepatic
fibrosis because of its multi-targeted inhibition of HSC activity in vivo and in vitro.
Abbreviations
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BDL, bile duct ligation; COL-I, collagen type I; ECM,
extracellular matrix; H&E, haematoxylin and eosin; HNHA, N-hydroxy-7-(2-naphthylthio)heptanomide; HSC, hepatic
stellate cell; SAHA, suberoylanilide hydroxamic acid; Tbil, total bilirubin;α-SMA, α-smooth muscle actin
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Introduction
Liver fibrosis is an overactive wound healing process in
which excessive connective tissue builds up in the liver and
results in the distortion of hepatic architecture and liver
failure (Branton and Kopp, 1999). Chronic liver injury acti-
vates and transforms quiescent hepatic stellate cells (HSCs),
which transdifferentiate into activated HSCs, called myofi-
broblasts, acquiring contractile, proliferative and fibrogenic
properties as the primary cellular source of extracellular
matrix (ECM) components in the liver (Moreira, 2007). As a
consequence, the excessive accumulation of ECM initiates
fibrosis by releasing inflammatory mediators such as PDGF,
TGF and connective tissue growth factor (Pellicoro et al.,
2012). Therefore, suppression of HSC activation and prolif-
eration as well as induction of apoptosis in activated HSCs
have been proposed as therapeutic strategies for the treat-
ment and prevention of hepatic fibrosis (Elsharkawy et al.,
2005).
Anti-fibrotic drugs are not efficiently taken up by acti-
vated HSCs and are often toxic to hepatic cells, producing
unwanted side effects, and there are no proven drugs to treat
liver fibrosis in patients (Bataller and Brenner, 2005). Recent
studies suggest that liver fibrosis can be blocked by induction
of histone hyperacetylation by histone deacetylase (HDAC)
inhibitors (Kaimori et al., 2010; Liu et al., 2013). We have
already described the HDAC inhibitor, N-hydroxy-7-(2-
naphthylthio)heptanomide (HNHA), as inhibiting nuclear
HDAC enzyme activity in human umbilical endothelial cells
and breast cancer cells, an effect that was accompanied by
histone hyperacetylation and cell cycle arrest, as well as inhi-
bition of ECM regulators such as MMPs (Kim et al., 2007; Park
et al., 2011). However, the effects of HNHA on the regulation
of fibrogenic responses in HSCs and liver fibrosis have not
been studied.
Models of liver injury following bile duct ligation (BDL) in
rats have been widely used to dissect the molecular mecha-
nisms underlying acute and chronic liver injury. Here, we
evaluated the biological effects of HNHA and other known
treatments on the fibrogenic responses, including the prolif-
eration, apoptosis and activation of mouse and human HSCs,
and have also evaluated the anti-fibrotic effect of HNHA in
liver fibrosis induced by BDL in rats.
Methods
Isolation and culture of HSCs
The livers of 6-week-old male C57BL/6 mice (Orient Bio Inc.,
Seong-nam, South Korea) were sequentially digested with
pronase (Roche Applied Science, Mannheim, Germany) and
type IV collagenase (Sigma-Aldrich, St Louis, MO, USA) by in
situ perfusion for primary HSC isolation. Hepatocytes were
removed by centrifuging the digested liver at 50× g for 3 min.
The non-parenchymal cells present in the supernatant were
laid on top of a gradient of arabinogalactan (Sigma-Aldrich;
with densities of 1.035, 1.045, 1.058 and 1.085), followed by
centrifugation at 74 000× g for 40 min at 25°C. The fraction
containing HSCs was recovered from the interface between
the medium (1.045) and the lowest density (1.035). The
purity of HSCs was evaluated by examining the characteristic
stellate shape of the cells with phase contrast microscopy
and by the presence of lipid droplets by autofluorescence
using an excitation light of 320 nm. The viability of HSCs
assessed by Trypan blue staining always exceeded 95%.
Primary mouse HSCs were cultured in DMEM (Life Technolo-
gies, Inc., Grand Island, NY, USA) with 10% FBS and 100
units·mL−1 penicillin-streptomycin and were maintained at
37°C in an atmosphere of 5% CO2. We grew human primary
HSCs from human resection specimens (Sciencell, San Diego,
CA, USA) and used them for up to five passages. For experi-
ments, we plated cells at a density of 3 × 104 cells·cm−2. When
the cultures reached 70–80% confluence, they were trypsi-
nized and passaged.
Cell proliferation assay, cell viability assay
and cell cycle phase distribution by flow
cytometric DNA analysis
Mouse or human primary HSCs were pre-cultured for 24 h at
a density of 2.3 × 105 cells·mL−1 and the growth medium was
replaced with an experimental medium containing ibupro-
fen, meloxicam, suberoylanilide hydroxamic acid (SAHA) or
HNHA at final concentrations of 10 μM in cell proliferation
assay and cell cycle analysis, or ranging from 1 to 160 μM in
the cell viability assay. Growth medium containing 0.1%
(v/v) saline was used as a vehicle control. These assays were
performed as previously described (Park et al., 2011).
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Western blot analysis
Western blots were carried out as previously reported by Park
et al. (2011) using primary antibodies against Bcl-2, Bcl-w,
Bcl-xL, HDAC1, HDAC4, Bad, Bax, Bak, COX-2, cyclin D1 (all
from Abcam, Cambridge, UK); phospho-IκB-α (Cell Signaling
Technology, Danvers, MA, USA); phospho-NF-κB p65, IκB-α
(from Santa Cruz Biotechnology, Santa Cruz, CA, USA); p21
and p53 (Abcam); pro-caspase-3 and cleaved-caspase-3, pro-
caspase-7 and cleaved-caspase-7, pro-caspase-8 and caspase-8,
pro-caspase-9 and cleaved-caspase-9 (all from Santa Cruz Bio-
technology), collagen type I (COL-I) (R&D Systems, Minne-
apolis, MN, USA), α-smooth muscle actin (α-SMA) (Abcam),
TGF-β1 (R&D Systems), MMP-2 and MMP-9 (Abcam), and
β-actin (Santa Cruz Biotechnology).
RNA extraction and RT-PCR
Total RNA prepared from HSCs was extracted with RNeasy
Mini Kit (Qiagen, Valencia, CA, USA), including treatment
with DNase I to prevent genomic DNA contamination using
RURBO DNA-free Kit (Ambion, Foster City, CA, USA) accord-
ing to the manufacturer’s instructions. RT-PCR was carried
out with total RNA (1 μg) using the one-step RT-PCR kit
(Qiagen) according to the manufacturer’s protocol. The
resultant cDNA was used to carry out 40 PCR cycles consist-
ing of 15 s at 95°C, 30 s at 57°C and 60 s at 72°C on an ABI
Prism 7000 sequence detection system (Applied Biosystems,
Foster City, CA, USA). The reactions were performed using
SYBR green 1 (Qiagen), using primers for p21 (forward
5′-tccacagcgatatccagaca-3′, reverse 5′-ggacatcaccaggattggac-
3′) and Gapdh (forward 5′-atcaagaaggtggtgaagcggaa-3′, reverse
5′-tggaagagtgggagttgctgttga-3′). Each PCR was set up in trip-
licate wells in a total volume of 25 μL. The reaction mixture
contained the cDNA equivalent of 20 ng total RNA. The
quantitative values of the genes of interest were normalized
using Gapdh as the endogenous reference, and fold-increase
over control values was calculated using the relative quanti-
fication method of 2−ΔΔCt.
Serum biochemistry
For testing the liver function, the activities of aspartate
transaminase (AST), alanine transaminase (ALT) and the con-
tents of total bilirubin (Tbil) in the serum were determined
after 3 weeks of experimental treatment using an automated
analyser (RA-XT; Technicon, Tarrytown, NY, USA).
Animals and experimental design
All animal care and experimental procedures complied with
local guidelines and were approved by the Animal Experi-
ments Committee of Yonsei University. All studies involving
animals are reported in accordance with the ARRIVE guide-
lines for reporting experiments involving animals (Kilkenny
et al., 2010; McGrath et al., 2010). A total of 111 animals (106
rats, 5 mice) were used in the experiments described here.
Male Sprague Dawley rats (Orient Bio Inc.) weighing 250–
300 g (7 weeks old) were used. All animals were housed in
cages (five mice or two rats per cage) for 7 days. The light
cycle was controlled to provide 12 h light and 12 h darkness;
temperature was 22°C and humidity was 40–60%. A standard
diet of rodent pellets and tap water (membrane-filter purified
and autoclaved) were provided ad libitum. Rats were anaes-
thetized with an i.m. injection of Zoletil (30 mg·kg−1; Virbac,
Carros, France). After a midline abdominal incision, the
common bile duct (CBD) was doubly ligated with 4-0 silk
sutures and cut with #11 blade. Sham operation was just
exposure of the CBD by passing the cotton applicator below
the foramen of Winslow. After saline irrigation, abdominal
closure was performed with continuous 3-0 silk suture. After
the surgical procedure, animals were divided into five groups
in efficacy experiments and survival experiments: sham
operation group (SHAM, n = 10); BDL (+Veh) group (n = 20),
in which saline was i.p. injected beginning at 24 h after BDL;
BDL + meloxicam group (n = 20), in which meloxicam was
i.m. injected at 1.6 mg·kg−1 beginning at 24 h after BDL; BDL
+ SAHA group (n = 20); and BDL + HNHA group (n = 20), in
which the treatments (30 mg·kg−1) were given i.p. 24 h after
BDL. All drugs were administered once every 3 days for 3
weeks, in efficacy experiments or until death, in survival
experiments. For in vivo toxicity experiments, meloxicam was
i.m. injected (1.6 mg·kg−1) or HNHA (30 mg·kg−1), beginning
at 24 h after the sham operation (n = 16).
Tissue preparation
After 3 weeks, all animals were killed, and the blood, spleens
and livers were collected and the organ weights were deter-
mined. Plasma was separated by centrifugation at 2300× g for
5 min at room temperature within 15 min of sample collec-
tion. Livers were sliced into several parts. Some were imme-
diately snap-frozen in liquid nitrogen for further analysis and
kept at −80°C. Other samples of liver were immersed into
10% neutral buffered formalin solution for histopathological
examinations.
Haematoxylin and eosin (H&E) staining,
Masson trichrome staining and
immunohistochemistry
Liver biopsy specimens fixed in 10% buffered formalin solu-
tion were embedded with paraffin. Sections (5 μm) were
stained with H&E. The degree of fibrosis was assessed with
Masson trichrome staining according to the protocol pro-
vided by the manufacturer (Sigma-Aldrich). This procedure
stains nuclei dark red, cytoplasm and muscle fibres red, and
ECM components blue.
Immunohistochemical analysis was conducted as previ-
ously reported (Park et al., 2011) using primary antibodies
against acetyl histone H3 (1:200; Cell Signaling Technology,
Beverly, MA, USA), HDAC-1 (1:200), COL-I (1:200; Cell Sign-
aling Technology), α-SMA (1:20), TGF-β1 (1:100; Abcam) and
COX-2 (1:500; Santa Cruz Biotechnology). The images were
quantified by image analysis using Metamorph 6.0 software
(Universal Imaging Corp., Downingtown, PA, USA) according
to the software manual. Total area of collagen-stained area
and its optical density were calculated from three fields of
every slide and compared between groups by non-parametric
statistical methods.
Data analysis
Data are expressed as means ± SEM, unless otherwise stated.
Statistical analysis was performed with SPSS software, version
11.5 (SPSS Inc., Chicago, IL, USA). Differences between means
were assessed by two-tailed Student’s t-test or by one-way
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ANOVA followed by Bonferroni’s multiple-comparison post hoc
test. P values lower than 0.05 were considered statistically
significant.
Materials
HNHA and SAHA (vorinostat) were provided by Dr H-J.
Kwon. Meloxicam and PDGF-B were purchased from R&D
Systems.
Results
HNHA inhibits the proliferation and
activation of HSCs and induces the cell cycle
arrest and apoptosis of HSCs
HNHA treatment for 1 week showed greater inhibition of
mouse and human primary HSC proliferation, a feature of
HSC activation, compared with ibuprofen (a non-selective
COX inhibitor), meloxicam (a COX-2 selective inhibitor) and
SAHA (another HDAC inhibitor) (Figure 1A and B).
To assess further the effects of HNHA on HSC activation,
the expression of COL-I, α-SMA and TGF-β1 in PDGF-
stimulated HSCs was examined by Western blot analysis.
Stimulation of mouse HSCs with PDGF (20 ng·mL−1) for 24 h
significantly induced the expression of α-SMA, TGF-β1 and
COL-I expression, activation markers of myofibroblasts.
HNHA treatment suppressed this increased expression of
α-SMA, TGF-β1 and COL-I in activated HSCs (Figure 1C).
Incubation with HNHA (10 μM) arrested mouse HSCs in
the sub-G0/G1 and G0/G1 phase (about 90%) more effectively
than the other compounds used (about 70%; Figure 1D).
Consistent with the observed effects on cell proliferation, this
concentration of HNHA also reduced the expression of
COX-2, the phosphorylation of IκB-α and NF-κB p65, and the
degradation of IκB-α in HSCs, unstimulated or stimulated
with PDGF, a key molecule in the sustained activation and
proliferation of HSC survival (Figure 1E). Furthermore, HNHA
induced p21 and p53, a well-known arrestor of the cell cycle,
but reduced cyclin D1, a positive regulator of the cell cycle
(Figure 1E, F, H). These results were compatible with the
concentration-dependent cytotoxicity of HNHA, which
induced greater loss of viability at low concentrations
(1–10 μM) than the other inhibitors used (Figure 1G and
Table 1).
To investigate pro-apoptotic signalling pathways acti-
vated following the incubation with these inhibitors, the
expression of pro- (Bad, Bax and Bak) and anti-apoptotic
(Bcl-2, Bcl-w and Bcl-xL) members of the Bcl-2 family and the
activation of caspase-3, caspase-7, caspase-8 and caspase-9,
major effectors in apoptosis, in HSCs as well as the expression
of HDACs (HDAC1 and HDAC4) were investigated by
Western blotting. HNHA led to increased expression of pro-
apoptotic members of the Bcl-2 family and cleavage of pro-
caspase in HSCs (Figure 1H), which are barely detectable in
PDGF-treated HSCs. Moreover, HNHA and SAHA almost abol-
ished PDGF-induced expression of anti-apoptotic members of
the Bcl-2 family and decreased HDAC protein levels, key
molecules in the signalling pathways of HSC survival, but
the COX inhibitors (ibuprofen and meloxicam) were less
effective.
HNHA restores liver function in BDL rats
BDL, the most commonly used animal model of obstructive
cholestasis, causes obstructive jaundice and cholestasis,
which over time leads to histological changes in the liver,
including the development of cirrhosis. After 3 weeks of BDL,
livers were grossly enlarged and had lost compliance, com-
pared with those from sham-operated rats. BDL caused a
significant increase in liver/body weight ratio, serum AST,
ALT and Tbil levels, compared with sham-operated rats. In
the BDL + HNHA group, the changes in body weights and
liver/body weight ratios were significantly less than in the
other groups (Table 2). The increased serum activities of AST,
ALT and the contents of Tbil were attenuated in the BDL +
HNHA group compared with the BDL, BDL + meloxicam or
BDL + SAHA groups (Table 3). In addition, there was no evi-
dence of systemic toxicity attributable to the doses of meloxi-
cam, SAHA and HNHA used here. These data suggest that
HNHA was the most effective agent for decreasing hepatic
damage after BDL in this liver fibrosis model.
HNHA ameliorates histopathological
deterioration and ECM accumulation
in BDL-liver
Each lobe of the BDL-liver was equally affected grossly by BDL
upon examination by light microscopy of liver sections
stained with H&E. There was marked architectural distortion
of lobular structure and extensive bile duct proliferation infil-
trating into hepatocytes with periportal fibrogenesis and
occasional fibrogenesis in the parenchymal area, suggesting
activation of HSCs. The groups treated with meloxicam,
SAHA or HNHA showed an overall reduction of pathological
changes compared with the BDL group. The BDL + HNHA
group showed a greater suppression of lower bile duct prolif-
eration and periportal fibrosis compared with the meloxicam
or SAHA-treated groups (Figure 2A). Because liver fibrosis is
characterized by an increased accumulation of ECM, mainly
collagens, we assessed the collagen contents based upon Mas-
son’s trichrome staining and Western blots for type I colla-
gen. Consistent with the histopathology, HNHA markedly
suppressed collagen accumulation in BDL rat livers
(Figure 2B) and COL-I expression (Figure 2C). This suggests
that HNHA improved the histological changes and reduced
ECM accumulation in liver fibrosis.
HNHA suppresses activation of
myofibroblasts induced by BDL
Because the appearance of α-SMA-positive myofibroblasts is
considered as a key event in the progression of liver fibrosis
and TGF-β1, predominantly expressed by HSCs, is a key
mediator for transdifferentiation, we assessed α-SMA or TGF-
β1-positive cells by morphometric quantification to ascertain
the accumulation of fibrogenic myofibroblasts. Activated
myofibroblasts, as shown by positive staining for α-SMA,
were predominant in the peri-ductular zone 1 area and, to a
lesser degree, in the peri-sinusoidal area in zone 2 and zone 3.
Immunohistochemical staining for TGF-β1 showed that the
positively stained brown-coloured cells were mainly prolifer-
ating bile ductules and limiting plate hepatocytes. However,
liver samples from rats treated with meloxicam, SAHA or
HNHA for 3 weeks after BDL showed less bile duct prolifera-
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tion and weak or no cytoplasmic immunostaining for α-SMA
(Figure 3A) compared with BDL rats. Liver sections from
meloxicam, SAHA and HNHA group rats showed weak or no
cytoplasmic TGF-β1 staining in bile duct epithelial cells and
limiting plate hepatocytes (Figure 3B). Treatment with HNHA
was more effective in suppressing α-SMA and TGF-β1 in BDL-
livers than treatment with meloxicam or SAHA. We then
compared COX-2 expression in liver tissue samples. With
vehicle treatment after BDL, COX-2 was expressed mainly in
the proliferating bile ductules and, to a lesser degree, in
Figure 1
Effects of HNHA on proliferation, apoptosis and activation of HSCs. (A, B) Cell growth assay of mouse (A) or human (B) primary HSCs using cell
counting. (C) Western blot analysis of HSC activation markers in mouse HSCs. (D) Cell cycle phase distribution by flow cytometric DNA in mouse
HSCs. (E) Western blot analysis of cell proliferation protein levels in activated mouse HSCs. (F) Quantitative RT-PCR analysis of p21 in activated
mouse HSCs. Mouse primary HSCs were cultured in complete media with increasing concentrations of drugs for 48 h. (G) Cell viability assay.
Mouse primary HSCs were cultured in complete media with increasing concentrations of drugs for 96 h (n = 3). (H) Western blot analysis of
apoptosis-related proteins and HDAC levels in mouse HSCs. In the experiments summarized in (C)–(F) and in (H), mouse HSCs were incubated
with ibuprofen, meloxicam, SAHA or HNHA at a final concentration of 10 μM. Data shown are means ± SD (n = 4 except for G). *P < 0.05,
**P < 0.01, ***P < 0.005 versus control or ibuprofen.
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hepatocytes. In livers from BDL rats receiving meloxicam,
SAHA or HNHA, there was decreased hepatic COX-2 expres-
sion (Figure 3C) with the lowest expression in the HNHA-
treated group. These results were confirmed by Western blot
analysis of total lysates of livers, which showed that produc-
tion of COL-I, α-SMA, TGF-β1, COX-2, MMP-2 and MMP-9
appeared to be most reduced in the BDL + HNHA group
compared with other groups (Figure 3D). The acetylation of
histone H3 in liver tissue was much stronger in the HNHA-
treated group than in the BDL group (Supporting Informa-
Table 1
Inhibition of HSC proliferation by drug treatments
Meloxicam (μM) SAHA (μM) HNHA (μM)
Mouse primary HSCs 54 (±1.0) 23 (±1.7) 15 (±1.0)
Human primary HSCs 50 (±1.1) 20 (±1.9) 12 (±1.1)
Each data point represents the mean IC50 value (±SD) from three independent experiments performed in triplicate using sulforhodamine B
to assay proliferation.
Table 2
Effects of HNHA on body and organ weight changes in BDL rats
Groups Body weight (g)
Organ weight
Liver (g) Spleen (g) Liver/body (%) Spleen/body (%)
SHAM Veh 346 ± 7.9 14.00 ± 0.29 1.07 ± 0.07 3.86 ± 0.11 0.30 ± 0.05
Meloxicam 368 ± 9.0 14.35 ± 0.33 1.12 ± 0.05 3.89 ± 0.10 0.30 ± 0.02
SAHA 360 ± 4.2 13.56 ± 0.19 1.08 ± 0.02 3.76 ± 0.05 0.29 ± 0.03
HNHA 353 ± 5.9 13.65 ± 0.17 1.03 ± 0.09 3.86 ± 0.07 0.29 ± 0.05
BDL Veh 298 ± 4.7 21.13 ± 1.02 2.09 ± 0.12 7.08 ± 0.95 0.70 ± 0.11
Meloxicam 308 ± 5.5*,## 18.00 ± 0.97*,## 1.80 ± 0.55*,## 5.84 ± 0.45*,## 0.58 ± 0.05*,#
SAHA 311 ± 6.4*,# 15.74 ± 0.51**,# 1.52 ± 0.43**,# 5.06 ± 0.41**,# 0.49 ± 0.52**,#
HNHA 324 ± 5.1** 14.05 ± 2.06*** 1.32 ± 0.55*** 4.33 ± 0.54** 0.40 ± 0.05**
Meloxicam was injected i.m. at a daily dose of 1.6 mg, and SAHA and HNHA were injected i.p. in rats at a dose of 30 mg·kg−1 once every
3 days for 3 weeks. Data shown are means ± SEM.
*P < 0.05, **P < 0.01, ***P < 0.005 versus BDL; #P < 0.05, ##P < 0.01 versus BDL + HNHA.
Table 3
Serum biochemistry
AST (IU·L−1) ALT (IU·L−1) Tbil (mg·L−1)
SHAM 69.73 ± 7.98 27.17 ± 4.84 1.1 ± 0.2
BDL 342.11 ± 81.92 104.84 ± 38.12 81.4 ± 29.7
BDL + meloxicam 189.45 ± 47.12*,## 79.48 ± 29.59*,## 68.4 ± 14.5*,##
BDL + SAHA 113.17 ± 19.75**,# 59.08 ± 18.22**,# 50.7 ± 11.1**,#
BDL + HNHA 98.35 ± 20.44** 46.35 ± 17.24*** 34.2 ± 9.5***
SHAM + meloxicam 77.35 ± 10.01 30.27 ± 4.01 1.8 ± 0.4
SHAM + SAHA 76.98 ± 9.24 29.59 ± 3.87 1.7 ± 0.4
SHAM + HNHA 76.14 ± 9.97 29.87 ± 3.99 1.6 ± 0.3
Meloxicam was injected i.m. at a daily dose of 1.6 mg, and SAHA and HNHA were injected i.p. in rats at a dose of 30 mg·kg−1 once every
3 days for 3 weeks. Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (Tbil) of sham-
operated (SHAM) and bile duct ligation (BDL) rats were determined. Data shown are means ± SEM (n = 25).
*P < 0.05, **P < 0.01, ***P < 0.005 versus BDL; #P < 0.05, ##P < 0.01 versus BDL + HNHA.
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tion Fig. S2), whereas the level of HDAC1 was decreased in
the HNHA-treated group compared with the BDL group (Sup-
porting Information Fig. S3).
HNHA increases survival of BDL rats
Meloxicam, SAHA and HNHA were injected i.p. to evaluate
their effect on the survival of BDL rat, over 63 days. The
survival rate of the HNHA-treated group was higher than that
of the other groups (Figure 4). Administration of the drug
treatments to rats without BDL did not affect survival, which
was the same as that for sham-operated animals, indicating
no systemic toxicity attributable to meloxicam, SAHA and
HNHA. These findings were consistent with the results of
histopathology or liver function analysis. Taken together,
these results showed that HNHA improved liver function and
overall survival of rats with BDL.
Figure 2
Effects of HNHA on histopathology and ECM accumulation of BDL-livers. (A) The histological changes in the livers of bile duct ligated (BDL) rats
as shown by haematoxylin and eosin (H&E) staining. (B, C) Representative staining (left) and densitometric analysis (right) of Masson’s trichrome
staining (B) and collagen staining (C) of liver tissues of BDL rats. Masson’s trichrome staining stains nuclei black, cytoplasm and muscle fibres red,
and ECM components blue. Negative control slides (IgG control) were treated with isotype-matched IgG. Quantitative data are shown as box and
whisker plots with the median indicated as a horizontal bar, first and third quartiles as the box and the range shown by the whiskers (n = 15).
*P < 0.05, **P < 0.01, ***P < 0.005 versus BDL; #P < 0.05, ##P < 0.01 versus BDL+HNHA.
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Discussion
The induction of apoptosis in activated HSCs has emerged as
a treatment strategy for liver fibrosis (Schuppan and Kim,
2013). HDAC inhibitors can modulate the expression of
apoptosis-related genes (Cao et al., 2001) and recent studies
have shown that HDAC4 is accumulated during HSC transdif-
ferentiation (Mann et al., 2007; Qin and Han, 2010). For this
reason, the inhibition of HDAC has been considered as a
promising suppressor of HSC proliferation and activation in
vitro and in vivo (Rombouts et al., 2002; Watanabe et al.,
2011). HNHA is a new synthetic HDAC inhibitor with better
pharmacological properties than other HDAC inhibitors
including SAHA and was more effective in inducing G1/S cell
cycle arrest in breast cancer cells, compared with SAHA (Kim
et al., 2007). The anti-proliferative effect of HNHA on HSCs
Figure 3
Effects of HNHA on myofibroblast activation in BDL-liver. Representative staining (left) and densitometric analysis (right) of α-SMA (A), TGF-β1 (B)
and COX-2 (C) staining of liver tissues of BDL rats. (D) Representative Western blot of COL-1, α-SMA, TGF-β1, COX-2, MMP-2 and MMP-9 in liver
tissues of BDL rats (n = 4). Quantitative data are shown as box and whisker plots with the median indicated as a horizontal bar, first and third
quartiles as the box and the range shown by the whiskers (n = 15 except for D). *P < 0.05, **P < 0.01 ***P < 0.005 versus BDL; #P < 0.05,
##P < 0.01 versus BDL + HNHA.
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appeared also to be mediated through cell cycle arrest. In
concordance with the earlier data, we found here that HNHA
suppressed cell proliferation and increased, very effectively,
cell cycle arrest at the G0/G1 phase in mouse and human
primary HSC proliferation than ibuprofen, meloxicam or
SAHA. These results were related to an increase in the endog-
enous cyclin-dependent kinase inhibitor, p21, and p53 and
accompanied by a decrease in cyclin D1 expression by HNHA,
which led to profound inhibition of HSC growth. It is well
established that histone hyperacetylation induces apoptosis
via p21, whose promoter is amplified from acetylated histone
H3- or H4-associated chromatin by HDAC inhibition
(Blagosklonny et al., 2002). HNHA also strongly rescued
histone acetylation in FM3A and MCF-7 cells (Kim et al.,
2007; Park et al., 2011), a function possibly linked to its
ability to arrest the cell cycle in HSCs.
Several cytokines are central to the pathogenesis of fibro-
sis and the process of HSC activation, particularly PDGF and
TGF-β1. PDGF induces the activation of the downstream sig-
nalling kinase ERK in activated HSCs, which is associated
with myofibroblast differentiation, cell proliferation and
stimulation of ECM production, the most important event in
tissue fibrogenic progression (Marra et al., 1999; Friedman,
2000; Reif et al., 2003). Simultaneously, inhibition of PDGF
signalling pathways have also been shown to induce HSC
apoptosis and attenuate liver fibrosis (Borkham-Kamphorst
et al., 2004). Furthermore, Bcl-2 enhances the resistance to
apoptosis in activated HSCs, which may contribute to the
development of fibrosis, while increased HSC apoptosis was
associated with reduced anti-apoptotic Bcl-2 expression in
the liver (Novo et al., 2006). HNHA showed marked inhibi-
tion of HSC activation and Bcl-2 expression and led to acti-
vation of caspases in PDGF-stimulated HSCs. Therefore, our
results suggested that HNHA not only significantly inhibited
the proliferation and activation of HSCs through suppression
of NF-κB activation but also had a marked apoptotic effect on
HSCs through inhibition of Bcl-2 activation, which is impor-
tant for fibrogenesis.
Quiescent HSCs do not express COX-2 but activated HSCs
do express COX-2, suggesting that the COX-2/PG pathway is
involved in hepatic fibrogenesis (Rahman et al., 2000; Cheng
et al., 2002). Because the effects of non-selective COX inhibi-
tors such as ibuprofen on the fibrogenic response in HSCs and
in the liver still remain controversial (Rahman et al., 2000;
Cheng et al., 2002), specific inhibition of COX-2 would
appear to be safer. Recent studies reported that selective
COX-2 inhibitors, including meloxicam, suppressed prolif-
eration of human HSCs (Furst, 1997). Interestingly, inhibitors
of HDAC suppress COX-2 expression by blocking the induc-
tion of c-Jun and lead to the inhibition of viability and the
induction of apoptosis (Yamaguchi et al., 2005). In our
experiment, HNHA mainly acted on portal myofibroblasts in
cholestasis, by suppressing COX-2 in bile duct epithelium,
resulting in diminished collagen formation in activated
myofibroblasts. As shown by histology and image analysis of
collagen formation in the present study, HNHA showed pow-
erful repression of bile duct proliferation and periportal fibro-
sis. Cholestatic liver fibrosis led to hepatocyte apoptosis/
necrosis during acute liver damage, transformation of portal
fibroblast or HSCs to activated forms of myofibroblasts pro-
ducing ECM, proliferation of bile duct and increase in secre-
tion of cytokines such as PDGF and TGF-β (Ramm et al.,
2009). In our experiments, TGF-β1 was strongly stained in
hepatocyte and HSCs and, to a lesser degree, in cholestatic
liver, and this staining was diminished by HNHA administra-
tion. Consequently, HNHA suppressed α-SMA expression and
collagen formation in cholestasis induced by BDL as well as
PDGF and TGF-β, effects confirmed in primary HSCs. In addi-
tion to expressing type I collagen, activated HSCs also express
MMPs, which are important in the ECM remodelling that
accompanies most liver diseases. Our previous study demon-
strated that treatment of tumour cell lines with the HDAC
inhibitor resulted in modulation of secreted MMP-2 and
MMP-9, accompanied by global histone H3 and H4 hypera-
cetylation (Rodriguez-Salvador et al., 2005). As shown in our
present experiments, HNHA inhibited MMP-2 and MMP-9
production in activated HSCs and BDL livers. Because of their
role in fibrosis, the inhibition of TGF-β, α-SMA, MMP and
COX-2 expression in the present study showed that HNHA
could be an effective treatment for fibrotic diseases.
HNHA showed no toxic effect on hepatocytes at the con-
centrations used in this study (data not shown) and restored
the body weight of BDL rats. In addition, a hepatoprotective
activity of HNHA was expressed through the reduction in
ALT, AST and TBil, which offers an additional therapeutic
advantage of HNHA, compared with the other treatments, as
it could both improve hepatocyte integrity and reduce stel-
late cell activation, as two independent but complementary
activities. Furthermore, HNHA increased survival in BDL rats.
As HNHA itself did not affect liver function and improved
survival of BDL rats, this HDAC inhibitor may serve both for
the chemoprevention and for the treatment of biliary fibrosis.
In conclusion, we have demonstrated that treatment with
HNHA, a new HDAC inhibitor, markedly attenuated the
process of liver fibrosis both in vitro and in vivo, showing a
marked decrease of HSC proliferation and increased apopto-
sis, as well as suppression of profibrogenic factors such as
PDGF and TGF-β1. Our data also provided the first in vivo
evidence that HNHA increased survival in the BDL-induced
Figure 4
Effects of HNHA on survival in BDL rats. Kaplan–Meier plot for overall
survivals. Differences between survival curves for 63 days in groups
(SHAM group, n = 10; SHAM + HNHA, n = 16; BDL group, n = 20;
BDL + meloxicam group, n = 20; BDL + SAHA group, n = 20;
BDL + HNHA group, n = 20) were compared using a log-rank test.
***P < 0.005 versus BDL.
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liver fibrosis model. Although further studies to determine
drug doses from long-term studies are clearly required, our
present results encourage the development of HNHA as a
possible treatment for hepatic fibrosis.
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Figure S1 Quantification of Western blots. The box and
whisker plots show median, with first and third quartiles (as
box) and range (as whiskers). Data are from n = 4 experi-
ments. *P < 0.05, **P < 0.01, ***P < 0.005 versus PDGF, control,
or BDL.
Figure S2 Effects of HNHA on acetylation of histone H3 in
BDL-liver. Representative staining (A) and densitometric
analysis (B) of acetyl histone H3. The box and whisker plots
showmedian, with first and third quartiles (as box) and range
(as whiskers). Data are from n = 5 experiments. *P < 0.05,
**P < 0.01, ***P < 0.005 versus BDL.
Figure S3 Effects of HNHA on levels of HDAC1 in BDL-liver.
Representative staining (A) and densitometric analysis (B) of
HDAC1 levels. The box and whisker plots show median, with
first and third quartiles (as box) and range (as whiskers). Data
are from n = 5 experiments. **P < 0.01, ***P < 0.005 versus
BDL.
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